![Han Hoon](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Han Hoon
Direktor/Vorstandsmitglied bei The Korean Society for Biomaterials
Aktive Positionen von Han Hoon
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AsiaCORD | Corporate Officer/Principal | 17.10.2011 | - |
Society for Hematology & Stem Cells | Corporate Officer/Principal | 17.10.2011 | - |
The Korean Society for Biomaterials | Direktor/Vorstandsmitglied | 17.10.2011 | - |
Karriereverlauf von Han Hoon
Ehemalige bekannte Positionen von Han Hoon
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Stem Cell Therapy International, Inc.
![]() Stem Cell Therapy International, Inc. Miscellaneous Commercial ServicesCommercial Services Stem Cell Therapy International, Inc. is a surgical procedure that has been used successfully for 70+ years as a treatment of many diseases for which modern medicine has had no therapy, or in which 'state-of-art' therapies stopped being effective. A documented 5 millions of patients have been so treated worldwide to-date, evidenced by over 120,000 publications in MEDLINE amongst others. SCT is approved for use by the German authorities and the EU. | Vorsitzender | 10.02.2010 | 23.02.2010 |
AmStem Corp.
![]() AmStem Corp. Pharmaceuticals: OtherHealth Technology AmStem Corp. researches and develops stem cell transplantation therapy and regenerative medicine. The company owns cord blood stem cell bank in Korea. The company was founded on December 28, 1992 and is headquartered in San Francisco, CA. | Vorsitzender | 13.09.2010 | - |
Independent Dir/Board Member | 10.09.2010 | - | |
Hucord Co., Ltd.
![]() Hucord Co., Ltd. BiotechnologyHealth Technology Hucord Co., Ltd. is a biotechnology company engaged in human cell-based therapy. It develops stem cell technology along with the cord blood, specializing in Multi-Lineage Progenitor Cells (MLPCs) research, treatment of disease and banking of cells. The group works in the following divisions: cord blood banking, stem cell banking, stem cell research and development, stem cell therapy management and the immunogenetics laboratory. It also performs the Human leukocyte antigen typing method which determines the compatibility of tissues between patient and the donor. The company was founded on January 24, 1979 and is headquartered in Yongin-si, South Korea. | Vorstandsvorsitzender | 01.02.2000 | - |
Gründer | 07.05.2010 | - |
Ausbildung von Han Hoon
Catholic University of Korea | Doctorate Degree |
Statistik
International
Südkorea | 4 |
Vereinigte Staaten | 4 |
Thailand | 2 |
Operativ
Chairman | 2 |
Doctorate Degree | 2 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 3 |
Commercial Services | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
![]() | Health Technology |
Private Unternehmen | 5 |
---|---|
Stem Cell Therapy International, Inc.
![]() Stem Cell Therapy International, Inc. Miscellaneous Commercial ServicesCommercial Services Stem Cell Therapy International, Inc. is a surgical procedure that has been used successfully for 70+ years as a treatment of many diseases for which modern medicine has had no therapy, or in which 'state-of-art' therapies stopped being effective. A documented 5 millions of patients have been so treated worldwide to-date, evidenced by over 120,000 publications in MEDLINE amongst others. SCT is approved for use by the German authorities and the EU. | Commercial Services |
AmStem Corp.
![]() AmStem Corp. Pharmaceuticals: OtherHealth Technology AmStem Corp. researches and develops stem cell transplantation therapy and regenerative medicine. The company owns cord blood stem cell bank in Korea. The company was founded on December 28, 1992 and is headquartered in San Francisco, CA. | Health Technology |
AsiaCORD | |
Society for Hematology & Stem Cells | |
The Korean Society for Biomaterials |